The need for non-pharmaceutical pain management techniques and the rise in chronic pain issues have led to a significant expansion in the spinal cord stimulator market sales in recent years. Medical devices called spinal cord stimulators (SCS) use electrical impulses to inhibit pain signals in the spinal cord. These devices are used to treat conditions like failed back surgery syndrome, neuropathic pain, and complex regional pain syndrome.
By 2033, the spinal cord stimulators market is projected to generate US$5,441.4 million in sales. According to our healthcare experts, spinal cord stimulator vendors should anticipate a strong compound annual growth rate (CAGR) of 7.2% through 2033, with a 2023 current valuation of US$ 2,702.7 million.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2030
Spinal cord stimulation is one of the most effective methods for managing chronic pain. The rising prevalence of chronic pain and the cost-effectiveness of spinal cord stimulators, as well as better reimbursement policies, companies’ emphasis on product promotion, and the effectiveness of spinal cord stimulators in reducing opioid analgesic use, are expected to drive the spinal cord stimulators market.
Spinal cord stimulation is considered one of the most effective methods to cure chronic pain management. Owing to the rising prevalence of chronic pain and cost-effectiveness of spinal cord stimulators, better reimbursement policies, companies’ focus on promoting their product, and the effectiveness of spinal cord stimulators in reduction of opioid analgesics use are expected to boost the spinal cord stimulators market.
Key Takeaways
- The growth of the spinal cord stimulation market is expected to be driven by regular enhancements in technologies, the broad availability of healthcare facilities, and non-invasive treatments/surgeries. The government’s initiatives and policies are also acting in the favor of the market.
- Meticulous research and development enable manufacturers to cope with the growing demand and utilize newer technologies in the market. Various treatments like stem cell therapy and functional electrical stimulation (FES) have shown promising results in paralyzed patients. FES treatment utilizes a computer and electrodes in order to give small electronic bursts to paralyzed muscles for their stimulation and movement.
- According to the studies, the most utilized therapy is known as “HF10” which is proven to be a successful treatment in spinal cord stimulation. This technology is deployed for conditions typically treated with spinal cord stimulators (SCS), especially chronic low back and leg pain. Owing to its effective and instant relief, this type of treatment is gaining traction rapidly.
- In addition to that, there is a significant rise in awareness among physicians & patients and the introduction of technologically advanced devices is the major factor driving the growth of the spinal cord stimulators market.
- Failed back surgery syndrome is efficiently treated by spinal cord stimulators, complex regional pain syndrome, and ischemic limb pain. Spinal cord stimulation therapy is designed in such a way that delivers low-voltage electrical pulses to stimulate the spinal cord nerve fibers that are involved in the body’s neural pain signal pathway. By stimulating these nerves, the delivery of pain messages to the brain is interrupted, therefore, providing the patient with a diminished sensation of pain.
Key Players:
- Medtronic Public Limited Company,
- Boston Scientific Corp,
- St Jude Medical LLC and Nevro Corp,
- Nuvectra Corporation and Stimwave,
- Neurosigma Inc.,
- Synapse Biomedical Inc.,
- Abbott Laboratories,
- Beijing PINS Medical Co., Ltd,
- Cirtec Medical Corporation,
- Gimer Medical,
- Bluewind Medical,
- Bioinduction,
- Greatbatch, Inc.,
- Saluda Medical Pty Ltd.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-2030
Spinal Cord Stimulators Segments:
Products:
- Rechargeable
- Non-Rechargeable
Application:
- Failed back Surgery Syndrome
- Complex Regional Pain Syndrome
- Ischemic Limb pain
- Others
End User:
- Hospitals
- Ambulatory Surgical Centers
- Clinics
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
